University of Edinburgh Launches EDRS Clinical Trial to Investigate Mechanisms Reversing Pancreatic Lipotoxicity
Study Overview and Background
The Edinburgh Diabetes Remission Study (EDRS, NCT07364045), led by Dr. Ahmad Al-Mrabeh at the University of Edinburgh, is a mechanistic clinical trial that commenced recruitment on January 30, 2026. This study aims to directly measure the pathway by which pancreatic lipotoxicity induces beta cell dysfunction in obesity-induced type 2 diabetes (T2D) and to elucidate the mechanisms by which this process is reversed through weight loss. Dr. Al-Mrabeh has received the MRC Career Development Award and the BHF Transition Research Fellowship, and has designed a study that builds upon Professor Roy Taylor's (Newcastle University) Twin Cycle Hypothesis.
Clinical Design and Key Endpoints
A total of 104 participants will be divided into four groups: non-diabetic, pre-diabetic, short-term T2D, and long-term T2D. They will undergo an 8-12 week weight loss program of 10-15% using an 800 kcal/day total diet replacement (TDR), followed by a 6-12 month maintenance period. The primary endpoints are changes in de novo lipogenesis (DNL) in the liver, VLDL1-triglyceride (VLDL1-TG) export dynamics, and the remission rate of diabetes, assessed through MRI-based quantification of pancreatic fat. A multi-modality approach, including a mixed meal test and adipose tissue biopsy, is a key feature.
Prior Clinical Evidence: DiRECT and ReTUNE
EDRS is a follow-up mechanistic study to the DiRECT (Diabetes Remission Clinical Trial), which was led by Professor Roy Taylor. In DiRECT, approximately 86% of participants who lost 15 kg or more achieved T2D remission, with overall remission rates of 46% at 1 year, 36% at 2 years, and 13% at 5 years in an extended follow-up (Lancet Diabetes & Endocrinology, 2024). The ReTUNE study demonstrated that remission is possible in T2D patients with a BMI of less than 27 using an 800 kcal low-calorie diet, suggesting that the mechanism of weight loss is not simply reducing overall obesity, but rather removing ectopic fat in organs.
Industrial Impact: DNL Inhibitors and the GLP-1 Market
If EDRS proves that the DNL pathway is a key mediator of T2D remission, it will strengthen the evidence for expanding the indications for fatty acid synthase (FASN) inhibitors and acetyl-CoA carboxylase (ACC) inhibitors. Sagimet Biosciences' (SGMT) denifanstat (TVB-2640), a FASN inhibitor, met its primary endpoint in the MASH Phase 2b (FASCINATE-2) trial and is scheduled to enter a Phase 2 trial for F4 MASH and a Phase 3 trial for acne in the second half of 2026. With the GLP-1 receptor agonist market projected to grow from $66.4 billion in 2025 to $185.3 billion in 2033, the results of EDRS could provide scientific evidence for lipid metabolism-targeted therapies that are distinct from GLP-1. The primary completion date is March 2029.
EDRS is the first prospective, multi-modality clinical trial to quantitatively elucidate the specific lipid pathway of liver DNL → VLDL1-TG export → pancreatic fat accumulation in the process by which weight loss induces T2D remission. By elucidating the molecular mechanisms of remission demonstrated by DiRECT, it provides a biomarker-based foundation for the pre-clinical and clinical design of drugs such as Sagimet's (SGMT) denifanstat, which could expand into T2D indications. In 2025, T2D accounts for 81.2% of the $66.4 billion GLP-1 market, and lipid metabolism-targeted new drugs can target patients who are intolerant to GLP-1 or combination therapy. However, EDRS is a mechanistic study based on non-pharmacological dietary interventions, and it does not directly lead to drug approval, but rather establishes the scientific validity of subsequent targeted therapies, so the investment timeline should be judged based on the data release after 2029.
Source: ClinicalTrials.gov (api_ct)